Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.41 |
| ▸ | CDK2 | P24941 | 6/20 | 0.41 |
| ▸ | GSK3B | P49841 | 5/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | VNN1 | O95497 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31512343 | 0.80 | BCHE (0.41) | L3MBTL1CCNE1CDK2GSK3BEPHX1 | |
| SCHEMBL13150540 | 0.80 | L3MBTL1 (0.44) | L3MBTL1CCR2EPHX1 | |
| SCHEMBL31512380 | 0.78 | HPGD (0.46) | CA12CA1CA2CA9CCNE1 | |
| SCHEMBL30519075 | 0.78 | HPGD (0.46) | CA12CA1CA2CA9CCNE1 | |
| SCHEMBL5990752 | 0.77 | GPR119 (0.36) | CCNE1CDK2GSK3BHRH3 | |
| SCHEMBL12791467 | 0.77 | HPGD (0.45) | CCNE1CDK2GSK3BEPHX1 | |
| SCHEMBL20601119 | 0.75 | HPGD (0.50) | CA12CA1CA2CA9CCNE1 | |
| SCHEMBL19064614 | 0.74 | TSHR (0.56) | CA12CA1CA2CA9VNN1 | |
| SCHEMBL19064615 | 0.74 | TSHR (0.56) | CA12CA1CA2CA9VNN1 | |
| SCHEMBL12021701 | 0.74 | USP2 (0.53) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | BLUEPRINT MEDICINES CORPORATION | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074895-A1 | CDK2 INHIBITORS AND METHODS OF MAKING AND USING SAME | CDK2, CDK20, CDK2AP1 | CA12 2817/4885CA1 2419/4885CA2 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.